Comparisona | First author | RBD Abb | Spike protein Abb | Neutralizing Abb | T cell response and othersb | Conclusion |
---|---|---|---|---|---|---|
ChAd/BNT vs BNT/BNT | Louise Benning [21] | NS in MFI values | Higher MFI of full spike protein (24,243 vs 23,849), S1 protein (19,332 vs 16,955), and S2 protein (13,138 vs 9696) values Comparable anti-S1 IgG levels (116.2 to 145.5) dimensionless index | NS in inhibition of RBD-ACE2 binding (96.8% vs 97.0%) | NR | ChAd/BNT superior to BNT/BNT in spike protein Ab, while comparable in RBD and neutralizing Ab |
ChAd/BNT vs BNT/BNT | Joana Barros-Martins [12] | NR | NS in Anti-S IgG (625.7 vs 303.2 RU/ml by quantitative ELISA) and IgA (3.76 vs 2.56 ratio) | NR | NR | ChAd/BNT comparable to BNT/BNT in Anti-S IgG and IgA |
ChAd/BNT vs BNT/BNT | Xinxue Liu [14] | NR | NS in Anti-S IgG levels (12,995 vs 13,938 ELU/mL by ELISA) | NS in PNA NT50 (515 vs 574) | NR | ChAd/BNT comparable to BNT/BNT in Anti-S IgG levels and PNA NT50 |
ChAd/BNT vs BNT/BNT | Alexandre Vallée [28] | NR | NS in S protein IgG levels (7268.6 vs 10,734.9 RLU by CMIA) | NR | NR | ChAd/BNT comparable to BNT/BNT in S protein IgG |
ChAd/BNT vs BNT/BNT | David Hillus [13] | NS in anti-RBD IgG (5.6 vs 5.4S/Co by solid phase immunoassay) | NS in anti-full S and anti-S1 IgG Higher Anti-S1 IgG avidity index (93.6% vs 73.9%) | NS in ACE2–RBD binding inhibition (97.1% to 96.6%) Higher serum neutralising activity (ID50 against to alpha variant 956.6 vs 369.2, ID50 against to beta variant 417.1 vs 72.4) | Higher S-specific T-cell responses (IFN-γ: 4762 vs 2026 mIU/mL) | ChAd/BNT superior to BNT/BNT in serum neutralising activity and S-specific T-cell responses; Comparable in anti-RBD IgG, anti-full S, anti-S1 IgG and anti-S1 IgG avidity |
ChAd/BNT vs BNT/BNT | Dorit Fabricius [15] | NR | NR | Higher neutralization capacities against wildtype RBD and B.1.1.7 variant (82% to 63%) | Higher IFN-γ secretion | ChAd/BNT superior to BNT/BNT in neutralization capacities and T cells responses |
ChAd/BNT vs BNT/BNT | Matthias Tenbusch [27] | NR | NR | Higher surrogate neutralisation activity (IC50: 3377 to 1789AU/mL) | NR | ChAd/BNT superior to BNT/BNT in neutralisation Ab |
ChAd/BNT vs BNT/BNT | Swantje I. Hammerschmidt [23] | NR | NR | Lower reciprocal titers of neutralizing against Delta (180 to 540) | NR | ChAd/BNT inferior BNT/BNT in neutralisation Ab |
ChAd/(BNT or mRNA-1273) vs (BNT or mRNA-1273)/(BNT or mRNA-1273) | Tina Schmidt [26] | NS in IgG to RBD of S protein (3630 vs 4932 BAU/mL by ELISA) | NR | Higher in inhibition of ACE2-S1 RBD (100.07% to 99.68%) | Higher percentages of spike-specific IFN-γ-producing CD8 T cells levels (0.28% to 0.06%) NS in CD4 T cells levels (0.17% to 0.16%) | ChAd/BNT superior to mRNA-1273 in neutralizing Ab and CD8 T cells levels, while comparable in RBD Ab and CD4 T cells levels |
ChAd/mRNA-1273 vs BNT/BNT | Dorit Fabricius [15] | NR | NR | Higher neutralization capacities against wildtype RBD and B.1.351 variant (85% to 59%), B.1.1.7 variant (87% to 63%) | NR | ChAd/mRNA-1273 superior to BNT/BNT in neutralization capacities |
Comparison | First Author | RBD Ab | Spike protein Ab | Neutralizing Ab | T cell response and others | Conclusion |
ChAd/BNT vs BNT/BNT | Rudiger Gross [22] | NR | 8.1-fold higher quantified cumulative anti-spike-IgM and IgG concentrations (8815 vs 1086 U/ml) | 3.9-fold higher neutralizing activity correlated with IgG or IgM/G titres (2744 vs 709) | Levels of spike-specific CD8 + T cells producing IL-2 in agreement with BNT/BNT | ChAd/BNT superior to BNT/BNT in spike IgM and IgG and neutralizing activity, while comparable in T cell response |
ChAd/BNT vs BNT/BNT | Bruno Pozzetto [25] | NS in positivity rate of RBD IgG (both 100%) | NS in positivity rate of spike S1-specific IgG (both 100%); NS in S1-specific IgA levels (37.4 vs 46.7 ng/ml) | Higher neutralizing efficacy (99% vs 62%); 2.3-fold to 3.6-fold higher serum neutralizing antibody titres against different variants | Two fold higher in frequency of RBD-binding mBCs; higher in IgD–CD27+ (67% vs 47%); lower in IgG-switched mBCs (48% vs 62%); three times higher in proportions of CD21–CD11c+ subset; higher in proportions of frequencies of activated RBD-specific mBCs; similar in whole-blood IFNγ (0.43 vs 0.33 UI/ml) | ChAd/BNT superior to BNT/BNT in neutralizing efficacy, T cell response, and B cell activation |
ChAd/BNT vs BNT/BNT | Samantha J Westrop [29] | NR | NS in anti-S antibody level (6233 vs 5377), adjusted GMR:1.11 | NR | NR | ChAd/BNT inferior to BNT/BNT in anti-S IgG levels |
ChAd/mRNA-1273 vs mRNA-1273/mRNA-1273 | Swantje I. Hammerschmidt [24] | NR | NR | Lower in neutralizing antibodies against the Delta variant (540 vs 1620) | NR | ChAd/mRNA-1273 inferior to mRNA-1273/mRNA-1273 in neutralizing antibodies against Delta variant |
ChAd/BNT vs ChAd/ChAd | Louise Benning [21] | NR | Higher anti-S1 IgG levels (116.2 vs 13.1) by dimensionless index (CLIA) | Higher (96.8% vs 93.5%) in inhibition of RBD-ACE2 binding | NR | ChAd/BNT superior to ChAd/ChAd in S1 protein and neutralizing Ab |
ChAd/BNT vs ChAd/ChAd | Joana Barros-Martins [12] | NR | Higher Anti-S IgG (625.7 vs 160.9 RU/ml by quantitative ELISA) and IgA (3.76 vs 0.87 ratio) | Higher reciprocal titers of neutralizing antibodies against Wuhan (4840 vs 540), B.1.1.7 (540 vs 20), P.1 (60 vs 0) and B.1.351 (60 vs 0) variants | Higher in spike-specific CD4 + and CD8 + T cells Higher in IFN-γ concentration NS in spike-specific memory B cells NS in TNF-α concentration | ChAd/BNT superior to ChAd/ChAd in S protein, neutralizing Ab and T cellular response, while comparable in memory B cells and TNF-α |
ChAd/BNT vs ChAd/ChAd | Xinxue Liu [14] | NR | Higher in Anti-S IgG levels (12,995 vs 1387Â ELU/mL by ELISA), GMR: 9.3 | Higher in MNA NT50 titer (1269 vs 210), PNA NT50 titer (515 vs 61), GMR: 6.4 for MNA NT50 and 8.5 for PNA NT50 | Higher in T-cell ELISpot, SFC per million PBMCs (184 vs 48), GMR: 3.9 | ChAd/BNT superior to ChAd/ChAd in anti-S IgG levels, MNA NT50, PNA NT50, and cellular responses |
ChAd/BNT vs ChAd/ChAd | David Hillus [13] | Similar in anti-RBD IgG (5.6 vs 4.9 S/Co by solid phase immunoassay) | Higher Anti-S1 IgG avidity index (93.6% vs 71.7%) NS in anti-full S and anti-S1 IgG | Higher ACE2–RBD binding inhibition (97.1% vs 92.4%) Higher serum neutralising activity (ID50 against to alpha variant 956.6 vs 212.5, ID50 against to beta variant 417.1 vs 48.5) | Higher S-specific T-cell responses (IFN-γ:4762 vs 1061 mIU/mL) | ChAd/BNT superior to ChAd/ChAd in anti-S1 IgG avidity, serum neutralising activity and S-specific T-cell responses, while comparable in anti-RBD IgG, anti-full S and anti-S1 IgG |
Comparison | First Author | RBD Ab | Spike protein Ab | Neutralizing Ab | T cell response and others | Conclusion |
ChAd/BNT vs ChAd/ChAd | Dorit Fabricius [15] | NR | Higher Anti-S1 IgG and IgA | Higher neutralization capacities against wildtype RBD and B.1.1.7 variant (82% vs 48%), B.1.351 variant (70% vs 57%), P.1 variant (55% vs 15%) | Higher IFN-γ secretion | ChAd/BNT superior to ChAd/ChAd T in neutralization capacities and T cells responses |
ChAd/BNT vs ChAd/ChAd | Matthias Tenbusch [27] | NR | NR | Higher surrogate neutralisation activity (IC50: 3377 vs 106 AU/mL) | NR | ChAd/BNT superior to ChAd/ChAd in neutralisation Ab |
ChAd/BNT vs ChAd/ChAd | Swantje I. Hammerschmidt [23] | NR | NR | Higher reciprocal titers of neutralizing against Delta (180 vs 20) | NR | ChAd/BNT superior to ChAd/ChAd in neutralisation Ab |
ChAd/BNT or mRNA-1273 vs ChAd/ChAd | Tina Schmidt [26] | Higher IgG levels to RBD of S protein (3630 vs 404 BAU/mL by ELISA) | NR | Higher in inhibition of ACE2-S1 RBD (100.07% vs 83.37%) | Higher percentages of spike-specific IFN-γ-producing CD8 T cells levels (0.28% vs 0.04%) and CD4 T cells levels (0.17% vs 0.04%) | ChAd/BNT or mRNA-1273 superior to ChAd/ChAd in RBD Ab, neutralizing Ab, CD4 T cells, and CD8 T cells levels |
ChAd/BNT vs ChAd/ChAd | Samantha J Westrop [29] | NR | Higher in anti-S antibody level (6233 vs862), adjusted GMR:6.29 | NR | NR | ChAd/BNT superior to ChAd/ChAd in anti-S antibody |
ChAd/mRNA-1273 vs ChAd/ChAd | Swantje I. Hammerschmidt [24] | NR | NR | Higher in neutralizing antibodies against the Delta variant(540 vs 20) | NR | ChAd/mRNA-1273 superior to ChAd/ChAd in neutralizing antibodies against Delta variant |
BNT/ChAd vs BNT/BNT | Xinxue Liu [14] | NR | Lower anti-S IgG levels (7133 vs 13,938 ELU/mL by ELISA), GMR:0.51 | Lower PNA NT50 titer (383 vs 574), GMR:0.67 | NS in SFC per million PBMCs, T-cell ELISpot (90 vs 81), GMR: 1.2 | BNT/ChAd inferior to BNT/BNT in anti-S IgG levels and PNA NT50, while comparable in T cellular responses |
BNT/ChAd vs BNT/BNT | Samantha J Westrop [29] | NR | NS in anti-S antibody level (4776 vs 5377), adjusted GMR:0.80 | NR | NR | BNT/ChAd inferior to BNT/BNT in anti-S IgG levels |
BNT/ChAd vs ChAd/ChAd | Xinxue Liu [14] | NR | Higher anti-S IgG levels (7133 vs 1387ELU/mL by ELISA) | Higher PNA NT50 titer (383 vs 61) | NR | BNT/ChAd superior to ChAd/ChAd in anti-S IgG levels and PNA NT50 |
BNT/ChAd vs ChAd/ChAd | Samantha J Westrop [29] | NR | Higher in anti-S antibody level (4776 vs862), adjusted GMR:4.55 | NR | NR | BNT/ChAd superior to ChAd/ChAd in anti-S antibody |